FSD Pharma Files Investigational New Drug Application ('IND') with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates
businesswire.com
news
2022-05-31 00:00:00

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ('FSD Pharma' or the 'Company'), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announces the submission of an Investigational New Drug ('IND') application with the U.S. Food and Drug Administration ('FDA') and Health Canada detailing a planned Phase 2 clinical trial of FSD-PEA for the treatment of a yet-to-be-disclosed inflammatory disorder.

'Our current submissions of applications to FDA and Health Canada for FSD-201 efficacy trials represent a significant milestone in our drug development efforts,' said Zeeshan Saeed, Co-Founder and President of FSD Pharma.
